List of Sotyktu drug patents
Sotyktu is owned by Bristol.
Sotyktu contains Deucravacitinib.
Sotyktu has a total of 3 drug patents out of which 0 drug patents have expired.
Sotyktu was authorised for market use on 09 September, 2022.
Sotyktu is available in tablet;oral dosage forms.
Sotyktu can be used as treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy.
Drug patent challenges can be filed against Sotyktu from 2026-09-09.
The generics of Sotyktu are possible to be released after 07 November, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(10 years from now) | |
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 9, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 2026-09-09
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy
Dosage: TABLET;ORAL
SOTYKTU family patents
9
United States
4
Australia
3
Singapore
3
Japan
3
European Union
2
Portugal
2
Spain
2
Croatia
2
Mexico
2
Lithuania
2
Slovenia
2
Hungary
2
Poland
2
RS
2
Denmark
1
Turkey
1
Malaysia
1
Uruguay
1
Brazil
1
New Zealand
1
Philippines
1
Argentina
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
South Africa
1
Canada
1
Cyprus
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic